These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1039 related articles for article (PubMed ID: 26438444)

  • 1. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
    Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
    Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 5. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
    Hombach AA; Abken H
    Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
    [No Abstract]   [Full Text] [Related]  

  • 6. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
    Feldman SA; Assadipour Y; Kriley I; Goff SL; Rosenberg SA
    Semin Oncol; 2015 Aug; 42(4):626-39. PubMed ID: 26320066
    [No Abstract]   [Full Text] [Related]  

  • 8. A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.
    Valton J; Guyot V; Marechal A; Filhol JM; Juillerat A; Duclert A; Duchateau P; Poirot L
    Mol Ther; 2015 Sep; 23(9):1507-18. PubMed ID: 26061646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor T cell therapy: 25years in the making.
    Gill S; Maus MV; Porter DL
    Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 13. Advances in T-cell Immunotherapies.
    Stroncek DF; Reddy O; Highfill S; Panch SR
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):825-837. PubMed ID: 31466607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
    Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
    Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
    Hammill JA; Afsahi A; Bramson JL; Helsen CW
    Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive T cell therapy: points to consider.
    Yee C
    Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T cell therapy for cancer in the clinic.
    June CH
    J Clin Invest; 2007 Jun; 117(6):1466-76. PubMed ID: 17549249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-killing CAR therapies gain speed.
    Weber M
    Cancer Discov; 2015 Jan; 5(1):7. PubMed ID: 25583785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.